| Similar Articles |
|---|
 |
The Motley Fool
August 6, 2008
Brian Orelli |
Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out.   |
The Motley Fool
April 25, 2008
Brian Orelli |
Affymetrix Learns About Inertia Slower sales of its older chips drag down growth. |
The Motley Fool
April 24, 2008
Brian Orelli |
Illumina Ignites This biochip maker is on fire. |
The Motley Fool
October 25, 2007
Brian Orelli |
Turnaround at Affymetrix Affymetrix announces it is continuing its turnaround from an abysmal 2006 with another strong quarter. |
The Motley Fool
November 12, 2008
Brian Orelli |
Affymetrix Gets Specific The biochip maker announces that it will acquire privately held Panomics for $73 million in cash. |
The Motley Fool
February 6, 2008
Brian Orelli |
Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward? |
The Motley Fool
July 24, 2008
Brian Orelli |
Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth. |
The Motley Fool
July 25, 2008
Brian Orelli |
Affymetrix Astounds, in the Worst Way After taking a beating last quarter, biochip maker Affymetrix got pounded again in the second quarter, as its turnaround from the lows of 2006 fizzled out. |
The Motley Fool
February 4, 2009
Brian Orelli |
43% Growth! Yee-Haw! Illumina rocks another quarter. |
InternetNews
August 6, 2010 |
Microsoft-Salesforce Deal: Who Won? What's behind the settlement between a rising power in the cloud and software-as-a-service and software colossus Microsoft, which is trying to make its own inroads into the area? |
The Motley Fool
August 2, 2007
Brian Orelli |
98 Lawsuits Down, About 15,000 To Go Merck's Vioxx caseload just got a little smaller, when an appellate court ruled that 98 people from England and Wales could not sue in the U.S. Shares are up on the news. |
The Motley Fool
October 24, 2008
Brian Orelli |
Affymetrix Has Trouble Turning Around The problem is that Affymetrix doesn't sell sequencers, and no one seems to want the genome and RNA analyzers that it does sell. |
The Motley Fool
August 26, 2005
Stephen D. Simpson |
Merck Broaches the Obvious Merck will naturally end up settling many Vioxx cases, but the details are far from clear at this point. Investors, take note. |
The Motley Fool
September 11, 2008
Brian Orelli |
Vive le Vioxx Lawsuit Just when Merck thought it was finally done with lawsuits pertaining to Vioxx, it's gotten pulled back in. |
The Motley Fool
September 27, 2007
Brian Orelli |
Foreign Invasion of the Biochip Market A consortium of Japanese companies including Toshiba, and Canon are planning on jointly developing biochips for research and diagnostic purposes. |
The Motley Fool
November 13, 2007
Brian Orelli |
Merck: Case Closed? Now that Merck has settled its lawsuit, it can get back to business, focusing on continued growth from its cholesterol drugs, new diabetic medication, and cervical cancer vaccine. Investors, take note. |
The Motley Fool
April 27, 2007
Brian Orelli |
Making Money Off Your Competitors Affymetrix is looking appealing with a few new products and potential revenues from an unlikely source. Investors, take note. |
The Motley Fool
February 8, 2010
Brian Orelli |
An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement. |
The Motley Fool
August 7, 2006
Stephen D. Simpson |
Affymetrix: Price Always Matters Affymetrix has legit technology, but that doesn't mean it has infinite value for investors. |
The Motley Fool
January 3, 2012
Alex Planes |
Another Entry in the Genome Patent Rumble There's a whole lot of lawsuits going on. |
The Motley Fool
April 27, 2011
Brian Orelli |
Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby. |
The Motley Fool
October 24, 2007
Brian Orelli |
Illumina's Illuminating Results There was stellar revenue growth, but margins and stock compensations pulled the bottom line down. |
InternetNews
October 11, 2010 |
Microsoft Patent Licenses Aim to Avert Lawsuit On the eve of the launch of Windows Phone 7, Microsoft has licensed a host of patents relating to smartphone technology, including IP from Palm, in a bid to preempt infringement lawsuits. |
PC World
November 1, 2001
Sumner Lemon |
Microsoft, Government May Make a Deal Proposed antitrust settlement would give PC makers more control over Windows desktops; deal could be finalized on Friday... |
The Motley Fool
August 25, 2009
Brian Orelli |
That's How You Want to Spend Investors' Money? A high-growth buyback? Really? On the surface, the buyback of Illumina shares looks like a pretty poor use of capital, but in truth, the move might not be that bad for investors. |
The Motley Fool
April 22, 2009
Brian Orelli |
Illuminating Stock Option Problems Illumina's stock options are getting a little ridiculous. This problem was pointed out in the third quarter last year, and it doesn't seem to be going away. |
The Motley Fool
January 28, 2005
Karl Thiel |
Affymetrix Raking in the Chips The life sciences research chip maker is enjoying green pastures in the gene business. The company announced fourth-quarter revenues and profits that handily beat consensus expectations, and then gave an upbeat view of 2005. |
The Motley Fool
July 25, 2007
Brian Orelli |
Shiny Happy Illumina Illumina, which makes chips that can distinguish one million different genes, announced another stellar quarter. That makes eight in a row. |
BusinessWeek
February 20, 2006
Gene G. Marcial |
Fast Growth At Illumina Is In The Genes The company has become a rising star in the complex analysis of gene variation, and the stock shows it. |
The Motley Fool
October 22, 2008
Jim Mueller |
Illuminating Illumina Did the DNA analysis equipment maker miss, meet, or beat expectations? Well, it's complicated. |
The Motley Fool
March 18, 2008
Brian Orelli |
The Nuts and Bolts of Drug Research Merck just released a pair of papers detailing the network of proteins that are linked to obesity, but the pharmaceutical company won't benefit much financially from its studies. So who will? |
Chemistry World
January 8, 2013
Andrew Turley |
Illumina investment push Gene sequencing company Illumina has struck a $450 million deal to buy privately owned US firm Verinata Health, which specializes in non-invasive tests for early identification of fetal chromosomal abnormalities. |
Information Today
October 11, 2012
George H. Pike |
Google's Settlement With Publishers Does Not Resolve All Library Project Issues After more than 7 years of litigation, Google and The Association of American Publishers reached a settlement over Google's ongoing Library Project to scan books from public and academic libraries and make the content available over Google. |
The Motley Fool
July 26, 2007
Brian Orelli |
Affymetrix Advances New products and services should help Affymetrix regain market share. Yesterday, the company even announced a small second-quarter profit. |
The Motley Fool
May 2, 2011
Cindy Johnson |
Pacific Biosciences of California Shares Plunged: What You Need to Know Pacific Biosciences of California dropped 12% in intraday trading today after a news article on hot stock Illumina suggested industry competition is intensifying. |
The Motley Fool
July 22, 2009
Brian Orelli |
Levering the Genome Lower revenue can't stop Illumina from turning in a good bottom line. |
Wired
June 2000
Brian Alexander |
Biopoly Money Patents and strong-arm tactics are helping make Affymetrix the Intel of biochips. Along the way, Affy wants to turn DNA into a proprietary system. |
